The United States stock market has recently experienced a surge, with major indices like the Dow Jones and Nasdaq Composite showing significant gains amid optimism over reduced China tariffs and ...

Detailed price information for Kiniksa Pharmaceuticals International Plc (KNSA-Q) from The Globe and Mail including charting and trades.

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Armistice Capital lost almost 19% last month, the biggest decline for the hedge fund’s flagship money pool since its launch ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...

Diagnostica Stago, Inc., a global leader in hemostasis and thrombosis diagnostics, is pleased to announce a special educational webinar, "The Importance of Routine Coagulation Testing," in recognition ...

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

Scotiabank analyst Greg Harrison maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) today and set a price target of ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

A group of biotech CEOs, investors, and patient advocates have urged Senate HELP Committee Chairman Bill Cassidy (R-LA) to ...

Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...